TP53 and acute myeloid leukemia: These novel subgroups are, namely, (1) AML with mutations in genes encoding chromatin, RNA-splicing regulators, or both (18% of patients); (2) AML with TP53 mutations, chromosomal aneuploidies, or both (13%); and (3) AML with IDH2R172 mutations (1%).